GANX Gain Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: GANX

Price (delayed)

$2.96

Market cap

$48.01M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.71

Enterprise value

$37.24M

Gain Therapeutics, Inc. is redefining drug discovery with its See-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new ...

Highlights
Gain Therapeutics's debt has decreased by 19% YoY
GANX's equity has soared by 72% since the previous quarter but it is down by 33% year-on-year
GANX's quick ratio has soared by 60% QoQ but it is down by 31% YoY
GANX's revenue has plunged by 61% YoY
Gain Therapeutics's gross profit has shrunk by 61% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.gaintherapeutics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of GANX
Market
Shares outstanding
16.22M
Market cap
$48.01M
Enterprise value
$37.24M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.04
Price to sales (P/S)
697.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
674.93
Earnings
Revenue
$55,180
EBIT
-$22.19M
EBITDA
-$22.1M
Free cash flow
-$18.88M
Per share
EPS
-$1.71
Free cash flow per share
-$1.45
Book value per share
$0.97
Revenue per share
$0
TBVPS
$1.42
Balance sheet
Total assets
$18.61M
Total liabilities
$6.03M
Debt
$1.03M
Equity
$12.58M
Working capital
$12.83M
Liquidity
Debt to equity
0.08
Current ratio
3.59
Quick ratio
3.39
Net debt/EBITDA
0.49
Margins
EBITDA margin
-40,059.2%
Gross margin
100%
Net margin
-40,354.3%
Operating margin
-40,328.3%
Efficiency
Return on assets
-123.2%
Return on equity
-193%
Return on invested capital
-340.3%
Return on capital employed
-162.4%
Return on sales
-40,210.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GANX stock price

How has the Gain Therapeutics stock price performed over time
Intraday
1.02%
1 week
-2.31%
1 month
-25.81%
1 year
-42.64%
YTD
-9.34%
QTD
-21.49%

Financial performance

How have Gain Therapeutics's revenue and profit performed over time
Revenue
$55,180
Gross profit
$55,180
Operating income
-$22.25M
Net income
-$22.27M
Gross margin
100%
Net margin
-40,354.3%
GANX's revenue has plunged by 61% YoY
Gain Therapeutics's gross profit has shrunk by 61% YoY
The net income is down by 27% year-on-year
GANX's operating income is down by 25% YoY

Growth

What is Gain Therapeutics's growth rate over time

Valuation

What is Gain Therapeutics stock price valuation
P/E
N/A
P/B
3.04
P/S
697.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
674.93
The EPS has contracted by 16% YoY but it has grown by 6% from the previous quarter
GANX's equity has soared by 72% since the previous quarter but it is down by 33% year-on-year
The stock's price to book (P/B) is 31% less than its last 4 quarters average of 4.4
GANX's revenue has plunged by 61% YoY
The P/S is 4.2% lower than the last 4 quarters average of 728.3

Efficiency

How efficient is Gain Therapeutics business performance
Gain Therapeutics's return on equity has shrunk by 175% YoY and by 14% QoQ
GANX's return on assets has dropped by 114% year-on-year and by 8% since the previous quarter
The return on invested capital has dropped by 112% year-on-year and by 42% since the previous quarter

Dividends

What is GANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GANX.

Financial health

How did Gain Therapeutics financials performed over time
GANX's quick ratio has soared by 60% QoQ but it is down by 31% YoY
GANX's current ratio has surged by 56% since the previous quarter but it is down by 30% year-on-year
Gain Therapeutics's debt is 92% lower than its equity
GANX's equity has soared by 72% since the previous quarter but it is down by 33% year-on-year
GANX's debt to equity is down by 43% since the previous quarter but it is up by 14% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.